Antibody escape, the risk of serotype formation, and rapid immune waning: Modeling the implications of SARS-CoV-2 immune evasion.

Albright, Catherine; Van Egeren, Debra; Thakur, Aditya; Chakravarty, Arijit; White, Laura F; Stoddard, Madison

Albright, Catherine; Van Egeren, Debra; Thakur, Aditya; Chakravarty, Arijit; White, Laura F; Stoddard, Madison.

Afiliação

Albright C; Boston University, Boston, MA, United States of America.
Van Egeren D; Stanford University School of Medicine, Stanford, CA, United States of America.
Thakur A; Boston University, Boston, MA, United States of America.
Chakravarty A; Fractal Therapeutics, Cambridge, MA, United States of America.
White LF; Boston University School of Public Health, Boston, MA, United States of America.
Stoddard M; Fractal Therapeutics, Cambridge, MA, United States of America.

PLoS One ; 18(10): e0292099, 2023.

Article em En | MEDLINE | ID: mdl-37851632

Assuntos

COVID-19; SARS-CoV-2; Humanos; Evasão da Resposta Imune; Pandemias/prevenção & controle; Sorogrupo; Anticorpos Antivirais

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google